Open Access<p>Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade</p>
Author(s) -
Qian Yang,
Laichao Ni,
Saber Imani,
Zhangqiang Xiang,
Rui Hai,
Ruilin Ding,
Fu Shao,
Jing Wu,
Qinglian Wen
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s252181
Subject(s) - angiogenesis , protein kinase b , cell growth , cancer research , mapk/erk pathway , cd31 , chemistry , flow cytometry , apoptosis , signal transduction , microbiology and biotechnology , biology , biochemistry
Anlotinib is a highly potent multi-target tyrosine kinase inhibitor, with very good anti-tumor activity against a variety of solid tumors. However, its effect on colorectal cancer (CRC) is not yet clearly understood. The objective of this study was to investigate the anti-tumor effect and underlying mechanism of anlotinib in the pathogenesis of CRC.